Regents of the University of Minnesota v. AGA Medical Corp.

717 F.3d 929, 106 U.S.P.Q. 2d (BNA) 1982, 2013 WL 2378551, 2013 U.S. App. LEXIS 11077
CourtCourt of Appeals for the Federal Circuit
DecidedJune 3, 2013
Docket2012-1167
StatusPublished
Cited by63 cases

This text of 717 F.3d 929 (Regents of the University of Minnesota v. AGA Medical Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Regents of the University of Minnesota v. AGA Medical Corp., 717 F.3d 929, 106 U.S.P.Q. 2d (BNA) 1982, 2013 WL 2378551, 2013 U.S. App. LEXIS 11077 (Fed. Cir. 2013).

Opinion

DYK, Circuit Judge.

Appellant Regents of the University of Minnesota (“the University”) owns U.S. Patent No. 6,077,281 (“the '281 patent”) and U.S. Patent No. 6,077,291 (“the '291 patent”), which are directed to medical devices for repairing heart defects. The University accused AGA Medical Corporation (“AGA”) of infringing both patents. After claim construction, the district court granted summary judgment that the '291 patent was not infringed and that the asserted claims of the '281 patent were invalid as anticipated. The University appeals, arguing that the district court erred in its construction of the claims of the '291 patent, and in finding the '281 patent anticipated by a prior art device. We affirm.

BACKGROUND

The '291 and '281 patents are directed toward “septal occluders,” which are medical devices used to block holes in a thin wall of muscle and tissue (a “septum”) dividing two chambers of the heart. “Transcatheter” septal occluders can be delivered to the heart and positioned in a septal defect using a catheter threaded through a vein. In 1975, King and Mills received a patent on the first transcatheter septal occluder (“the King device”). U.S. Pat. No. 3,874,388 (filed Feb. 12, 1973).

In 1992, the University filed Patent Application No. 07/822,951 (“the '951 application”) claiming a transcatheter septal occluder invented by Dr. Gladwin Das. Four patents eventually issued from sue *933 cessive divisions of the '951 application, including U.S. Patent No. 5,334,217 (“the '217 patent”), issued in April 1994, another patent not at issue here, and the '291 and '281 patents, which were both issued in June 2000. The patents have different claims, but generally share the same specification. The “Summary of the Invention” explains that the claimed device has “first and second occluding disks which are attached to one another” centrally. '291 patent col. 3 11. 7-8; '281 patent col. 3 11. 11-12. Each disk comprises a membrane and a frame, and can be “collapsed” to fit in a catheter. '291 patent col. 3 11. 8-12. The device is delivered through the catheter to the heart, where it is positioned with one disk on each side of the defective septum. As the catheter is withdrawn, the disks expand, covering both sides of the defective septum and blocking the hole. See id. at col. 3 11. 10-14. The patents’ shared specification acknowledges prior art septal occluders with expandable membranes, including the patented King device and a device described in an article by Dr. James Lock (“the Lock device”). The Lock and King devices both have “umbrella-like” structures mounted on radial frames. The specification of the patents-in-suit disparages prior art radial frame devices as “mechanically complex and requiring] a great deal of remote manipulation for deployment,” '291 patent col. 2 11. 44^15; '281 patent col. 2 11. 48-49, and because the “single point or pivot” connecting the two umbrella structures can drift within the septal defect, allowing the device to become decentered. '291 patent col. 2 11. 52-56; '281 patent col. 2 11. 56-60.

In 2007, the University filed suit against AGA, alleging infringement of the '291 and '281 patents. AGA’s accused septal occluders are one-piece devices made from tubes of wire mesh. The mesh is molded into a preset shape with two large flat regions separated by a narrow waist. The device can be compressed into an elongated shape to fit in a catheter. Upon deployment from the catheter inside the heart, the device spontaneously springs back to the preset shape and blocks the septal defect.

At the parties’ request, the district court held a Maximum hearing and construed various disputed terms in the '291 and '281 patents. See Regents of the Univ. of Minn. v. AGA Med. Corp., 660 F.Supp.2d 1037 (D.Minn.2009). In January 2011, the court partially granted AGA’s motion for summary judgment of noninfringement, ruling that no reasonable jury could find that AGA’s one-piece mesh device infringed the '291 patent. Regents of the Univ. of Minn. v. AGA Med. Corp., No. 07-CV-4732, 2011 WL 13943, at *9, *15-16 (D.Minn. Jan. 4, 2011). In December 2011, the court granted AGA’s motion for summary judgment of invalidity with respect to asserted claims 1, 4, and 5 of the '281 patent, Regents of the Univ. of Minn. v. AGA Med. Corp., 835 F.Supp.2d 711 (D.Minn.2011), finding that all three claims were anticipated by the prior art Lock device, id. at 723-26. 1 The district court dismissed AGA’s remaining counterclaims as moot. Id. at 713-14. 2 The University *934 timely appealed, and we have jurisdiction pursuant to 28 U.S.C. § 1295(a)(1). Although the patents in this case are related, they present distinct legal issues on appeal, so we discuss them separately.

Disoussion

I. The '291 Patent

A. Claim construction

The dispute as to the '291 patent turns almost entirely on claim construction. Claim construction is a question of law, Markman v. Westview Instruments, Inc., 52 F.3d 967, 976-80 (Fed.Cir.1995) (en banc), aff'd, 517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996), which we review without deference, Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1454-55 (Fed.Cir.1998) (en banc).

Representative claim 1 of the '291 patent describes a septal occluder with two occluding disks “affixed” to one another at their centers, to “define a conjoint disk”:

1. A septal defect closure device comprising first and second occluding disks, each disk comprising a flexible, biologically compatible ‘ membrane capable of being collapsed for passage through a catheter and elastically returning to a predetermined shape for tautly holding a portion of the membrane against a septum; a central portion of the membrane of the first disk being affixed to a central portion of the membrane of the second disk to define a conjoint disk....

'291 patent col. 17 11. 54-61 (emphases added).

As shown in Figures 3 and 4, a preferred embodiment of the claimed invention comprises two membrane disks (20, 30), each having a jointed pentagonal frame (24) “attached to and desirably extending] substantially around .the periphery of the membrane.” '291. patent col. 5 11. 5-6. The flexible frames can be compressed to allow the device to pass through a catheter for delivery to the heart. As the catheter is withdrawn and the device is released, the frames expand to pull the membrane disks taut. Figure 3 depicts a side view of the device with the two membrane disks fully expanded (22, 32) and the smaller “conjoint disk” (40) between them:

[[Image here]]

*935 '291 patent figs. 3, 4.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
717 F.3d 929, 106 U.S.P.Q. 2d (BNA) 1982, 2013 WL 2378551, 2013 U.S. App. LEXIS 11077, Counsel Stack Legal Research, https://law.counselstack.com/opinion/regents-of-the-university-of-minnesota-v-aga-medical-corp-cafc-2013.